HMR Administers Canada's First Allogeneic CAR-T Therapy in Phase 1 Autoimmune Trial
Updated
Updated · Université de Montréal · May 26
HMR Administers Canada's First Allogeneic CAR-T Therapy in Phase 1 Autoimmune Trial
5 articles · Updated · Université de Montréal · May 26
A patient at Montreal's Hôpital Maisonneuve-Rosemont became the first in Canada this month to receive allogeneic CAR-T therapy for a severe autoimmune disease.
The treatment is being tested in the international Phase 1 Resolution trial for patients with lupus, myositis and scleroderma that have resisted standard therapies.
Unlike conventional CAR-T made from a patient's own cells, the HMR approach uses donor cells that can be prepared in advance and delivered without the weeks-long manufacturing delay.
HMR is the only Canadian site in the trial, with the program led by rheumatologist Dr. Nicolas Richard and hematologist Dr. Imran Ahmad.
Will this 'off-the-shelf' CAR-T therapy become an accessible cure or remain an impossibly expensive treatment for the few?
Donor T-cells often vanish within weeks. Has this new therapy truly solved the critical problem of long-term persistence?
If this immune-resetting therapy fails, could it leave patients even more vulnerable than they were before?
Canada Launches First Allogeneic CAR-T Clinical Trial for Autoimmune Diseases: Pioneering Scalable Cell Therapy in 2026
Overview
In May 2026, Canada reached a major milestone by administering its first allogeneic CAR-T cell therapy for patients with severe, treatment-resistant autoimmune diseases like lupus, myositis, and scleroderma. This innovative therapy, offered at Hôpital Maisonneuve-Rosemont (HMR) in Montreal, provides new hope for those who have not responded to standard treatments. HMR’s global expertise in stem-cell transplantation led to its selection as the only Canadian site in the international Phase 1 Resolution clinical trial, which is now evaluating the safety of this promising therapy and paving the way for future advances in autoimmune disease treatment.